JP7110096B2 - レトロウイルス産生のための一時的トランスフェクション法 - Google Patents
レトロウイルス産生のための一時的トランスフェクション法 Download PDFInfo
- Publication number
- JP7110096B2 JP7110096B2 JP2018526787A JP2018526787A JP7110096B2 JP 7110096 B2 JP7110096 B2 JP 7110096B2 JP 2018526787 A JP2018526787 A JP 2018526787A JP 2018526787 A JP2018526787 A JP 2018526787A JP 7110096 B2 JP7110096 B2 JP 7110096B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- retroviral
- vector
- acid vector
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 41
- 238000004519 manufacturing process Methods 0.000 title claims description 22
- 241001430294 unidentified retrovirus Species 0.000 title claims description 16
- 238000003146 transient transfection Methods 0.000 title description 12
- 239000013598 vector Substances 0.000 claims description 214
- 210000004027 cell Anatomy 0.000 claims description 137
- 150000007523 nucleic acids Chemical class 0.000 claims description 137
- 230000001177 retroviral effect Effects 0.000 claims description 118
- 102000039446 nucleic acids Human genes 0.000 claims description 106
- 108020004707 nucleic acids Proteins 0.000 claims description 106
- 108090000623 proteins and genes Proteins 0.000 claims description 87
- 239000002245 particle Substances 0.000 claims description 42
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 38
- 230000010076 replication Effects 0.000 claims description 35
- 108020004414 DNA Proteins 0.000 claims description 30
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 23
- 108700019146 Transgenes Proteins 0.000 claims description 21
- 208000031886 HIV Infections Diseases 0.000 claims description 20
- 239000012212 insulator Substances 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 11
- 241000713666 Lentivirus Species 0.000 claims description 10
- 102100034353 Integrase Human genes 0.000 claims description 9
- 108010078428 env Gene Products Proteins 0.000 claims description 9
- 230000001464 adherent effect Effects 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 8
- 101710177291 Gag polyprotein Proteins 0.000 claims description 7
- 101710125418 Major capsid protein Proteins 0.000 claims description 7
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 7
- 108010089520 pol Gene Products Proteins 0.000 claims description 7
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000004520 electroporation Methods 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- 238000001638 lipofection Methods 0.000 claims description 5
- 238000003151 transfection method Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- 241001663880 Gammaretrovirus Species 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 241001664176 Alpharetrovirus Species 0.000 claims description 3
- 241000713673 Human foamy virus Species 0.000 claims description 3
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims description 3
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- 208000010094 Visna Diseases 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 description 40
- 230000014509 gene expression Effects 0.000 description 25
- 230000001580 bacterial effect Effects 0.000 description 22
- 238000004806 packaging method and process Methods 0.000 description 17
- 238000012546 transfer Methods 0.000 description 17
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 15
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 13
- 241000701022 Cytomegalovirus Species 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 239000013603 viral vector Substances 0.000 description 11
- 108090000288 Glycoproteins Proteins 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 9
- 238000010361 transduction Methods 0.000 description 9
- 230000026683 transduction Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 108010077544 Chromatin Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 8
- 210000003483 chromatin Anatomy 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 7
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 7
- 210000004507 artificial chromosome Anatomy 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 101710149136 Protein Vpr Proteins 0.000 description 6
- 101710201961 Virion infectivity factor Proteins 0.000 description 6
- 108010061833 Integrases Proteins 0.000 description 5
- 108091092195 Intron Proteins 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 101710149951 Protein Tat Proteins 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 229960003722 doxycycline Drugs 0.000 description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108700004030 rev Genes Proteins 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 101100018382 Shigella flexneri icsP gene Proteins 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229940037201 oris Drugs 0.000 description 3
- 108700004029 pol Genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 101150098213 rev gene Proteins 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 101150022349 sopA gene Proteins 0.000 description 3
- 101150079130 sopB gene Proteins 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 241000713826 Avian leukosis virus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 101100278012 Escherichia coli (strain K12) dnaG gene Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101000650854 Homo sapiens Small glutamine-rich tetratricopeptide repeat-containing protein alpha Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 102000012330 Integrases Human genes 0.000 description 2
- 241000713326 Jaagsiekte sheep retrovirus Species 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101100165173 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) basS gene Proteins 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- 241000713880 Spleen focus-forming virus Species 0.000 description 2
- 101100421924 Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27) spo0C gene Proteins 0.000 description 2
- 241000713325 Visna/maedi virus Species 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 101150004979 flmA gene Proteins 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- -1 parA Proteins 0.000 description 2
- 101150048892 parB gene Proteins 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 101150034434 repE gene Proteins 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 108700004027 tat Genes Proteins 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241000951889 Autographa californica multiple nucleopolyhedrovirus Species 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001231757 Betaretrovirus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241001663879 Deltaretrovirus Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 241000702189 Escherichia virus Mu Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000725171 Mokola lyssavirus Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 101150101654 PSR1 gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241001115394 Reston ebolavirus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 102100022346 Serine/threonine-protein phosphatase 5 Human genes 0.000 description 1
- 101710129069 Serine/threonine-protein phosphatase 5 Proteins 0.000 description 1
- 101710199542 Serine/threonine-protein phosphatase T Proteins 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 241001115400 Zaire ebolavirus Species 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 108010087471 cin recombinase Proteins 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000530 impalefection Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920000470 poly(p-phenylene terephthalate) polymer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
- C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1520764.0A GB201520764D0 (en) | 2015-11-24 | 2015-11-24 | Transient transfection method for retroviral production |
| GB1520764.0 | 2015-11-24 | ||
| GB1609354.4 | 2016-05-26 | ||
| GBGB1609354.4A GB201609354D0 (en) | 2016-05-26 | 2016-05-26 | Transient transfection method for retroviral production |
| PCT/EP2016/078334 WO2017089307A1 (en) | 2015-11-24 | 2016-11-21 | Transient transfection method for retroviral production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500030A JP2019500030A (ja) | 2019-01-10 |
| JP2019500030A5 JP2019500030A5 (enExample) | 2020-01-09 |
| JP7110096B2 true JP7110096B2 (ja) | 2022-08-01 |
Family
ID=57348703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526787A Active JP7110096B2 (ja) | 2015-11-24 | 2016-11-21 | レトロウイルス産生のための一時的トランスフェクション法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10450574B2 (enExample) |
| EP (1) | EP3380605A1 (enExample) |
| JP (1) | JP7110096B2 (enExample) |
| KR (1) | KR102067352B1 (enExample) |
| CN (1) | CN108291211A (enExample) |
| AU (1) | AU2016359838B2 (enExample) |
| BR (1) | BR112018010639A2 (enExample) |
| CA (1) | CA3006285A1 (enExample) |
| DE (1) | DE102016122317A1 (enExample) |
| FR (1) | FR3044017B1 (enExample) |
| IL (1) | IL259223B (enExample) |
| IT (1) | IT201600117287A1 (enExample) |
| RU (1) | RU2749717C2 (enExample) |
| SA (1) | SA518391585B1 (enExample) |
| WO (1) | WO2017089307A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986051C (fr) * | 2015-05-15 | 2023-09-26 | Vectalys | Particule retrovirale comportant au moins deux arn non viraux encapsides |
| ES2939617T3 (es) * | 2015-11-24 | 2023-04-25 | Glaxosmithkline Ip Dev Ltd | Líneas celulares estables para producción retroviral |
| GB201706121D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
| GB201715052D0 (en) | 2017-09-19 | 2017-11-01 | Oxford Genetics Ltd | Vectors |
| ES2951857T3 (es) | 2017-12-22 | 2023-10-25 | Oxford Biomedica Ltd | Vector retroviral |
| GB201816919D0 (en) * | 2018-10-17 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Adeno-associated viral vector producer cell lines |
| CN110684804B (zh) * | 2019-10-15 | 2023-04-18 | 上海本导基因技术有限公司 | 递送外源rnp的慢病毒载体及其制备方法 |
| GB202004371D0 (en) | 2020-03-26 | 2020-05-13 | Glaxosmithkline Ip Dev Ltd | CAR constructs |
| GB202005096D0 (en) | 2020-04-07 | 2020-05-20 | Glaxosmithkline | Modified vectors for production of retrovirus |
| AU2021253701B2 (en) * | 2020-04-10 | 2024-05-02 | Southwest Research Institute | Three-dimensional bioreactor for viral vector production |
| CN117377691A (zh) | 2021-03-19 | 2024-01-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 靶向密蛋白3的嵌合抗原受体和治疗癌症的方法 |
| CN113373266B (zh) * | 2021-06-22 | 2022-07-01 | 内蒙古农业大学 | 一种用于检测绵羊肺腺瘤病毒的荧光rpa引物、试剂盒和检测方法 |
| WO2024218341A1 (en) | 2023-04-19 | 2024-10-24 | Glaxosmithkline Intellectual Property Development Limited | Cytotoxicity targeting chimeras for car-t and car-nk cells |
| WO2024218345A1 (en) | 2023-04-21 | 2024-10-24 | Glaxosmithkline Intellectual Property Development Limited | Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005512573A (ja) | 2001-10-30 | 2005-05-12 | バイレクシス コーポレイション | 調節された核酸発現系 |
| US20060057553A1 (en) | 2000-05-30 | 2006-03-16 | Estuardo Aguilar-Cordova | Chimeric viral vectors for gene therapy |
| JP2010517554A (ja) | 2007-02-12 | 2010-05-27 | アーク・セラピューティックス・リミテッド | レンチウイルスベクターの作製 |
| JP2015165810A (ja) | 2007-03-23 | 2015-09-24 | ウィスコンシン アラムニ リサーチ ファンデーション | 体細胞の再プログラム化 |
| JP2015529466A (ja) | 2012-09-14 | 2015-10-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| WO1995003400A1 (en) | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
| ATE309000T1 (de) * | 1995-06-27 | 2005-11-15 | Bavarian Nordic As | Verkapselte zellen die virenpartikeln produzieren |
| AU721326B2 (en) | 1996-02-13 | 2000-06-29 | Fred Hutchinson Cancer Research Center | 10A1 retroviral packaging cells and uses thereof |
| FR2751223B1 (fr) * | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
| US6277621B1 (en) | 1998-02-26 | 2001-08-21 | Medigene, Inc. | Artificial chromosome constructs containing foreign nucleic acid sequences |
| PT1141315E (pt) | 1998-12-31 | 2008-05-05 | Novartis Vaccines & Diagnostic | Polipéptidos do envelope (env) de hiv modificados |
| EP1179083A4 (en) | 1999-04-22 | 2003-04-23 | Gen Hospital Corp | TRIPLE HYBRID AMPLICON VECTOR SYSTEMS FOR THE PRODUCTION OF RETROVIRUS PACKING CELL LINES |
| US6677155B1 (en) | 1999-04-22 | 2004-01-13 | The General Hospital Corporation | Triple hybrid amplicon vector systems to generate retroviral packaging lines |
| CA2371946A1 (en) | 1999-04-29 | 2000-11-09 | Aarhus University | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
| CA2336590A1 (en) | 1999-06-07 | 2000-12-14 | Cell Genesys, Inc. | Hybrid yeast-bacteria cloning system and uses thereof |
| HK1050210B (en) | 1999-10-12 | 2007-08-24 | Institut Pasteur | Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| AU2001292711A1 (en) | 2000-09-18 | 2002-03-26 | Genetic Therapy, Inc. | Stress resistant retroviruses |
| US6586251B2 (en) * | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002053576A1 (en) | 2001-01-05 | 2002-07-11 | The General Hospital Corporation | Viral delivery system for infectious transfer of large genomic dna inserts |
| DE10111433A1 (de) | 2001-03-09 | 2002-09-19 | Bundesrepublik Deutschland Let | Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen |
| IL157746A0 (en) | 2001-05-30 | 2004-03-28 | Chromos Molecular Systems Inc | Chromosome-based platforms |
| JP4598398B2 (ja) | 2002-02-01 | 2010-12-15 | オックスフォード バイオメディカ （ユーケー） リミテッド | ウイルスベクター |
| ATE471382T1 (de) | 2002-04-10 | 2010-07-15 | Us Gov Health & Human Serv | Vac-bac-shuttlevektor-system |
| DE60314541T2 (de) * | 2002-11-25 | 2008-02-28 | Bavarian Nordic A/S | Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus |
| EP1743028A2 (en) * | 2004-04-28 | 2007-01-17 | The Trustees Of The University Of Pennsylvania | Polyvalent viral vectors and a system for production thereof |
| US20080226677A1 (en) | 2004-05-06 | 2008-09-18 | Yasuko Mori | Recombinant virus vector for gene transfer into lymphoid cells |
| EP1652932A1 (en) | 2004-11-02 | 2006-05-03 | GBF Gesellschaft für Biotechnologische Forschung mbH | Method for the generation of virus producing cell lines and cell lines |
| AU2005309485A1 (en) | 2004-11-24 | 2006-06-01 | Nanovector Limited | Viral vectors |
| PT2088193E (pt) * | 2004-11-24 | 2011-02-24 | Anaeropharma Science Inc | Novo vector vaivém |
| EP2062246A4 (en) | 2006-08-18 | 2010-09-29 | Univ North Carolina | VACCINES AGAINST CHIMARICAL VIRUSES |
| US20110027313A1 (en) | 2008-04-04 | 2011-02-03 | University Of Miami | Viral recombineering and uses thereof |
| SI2480678T1 (sl) * | 2010-09-02 | 2014-06-30 | Molmed Spa | Stabilno proizvajanje lentivirusnih vektorjev |
| US9273324B2 (en) | 2010-12-05 | 2016-03-01 | Andrew S. Belmont | Recombinant gene expression |
| WO2012170431A2 (en) | 2011-06-06 | 2012-12-13 | Bluebird Bio, Inc. | Improved geneswitch systems |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| US10590433B2 (en) * | 2014-03-14 | 2020-03-17 | University Of Washington | Genomic insulator elements and uses thereof |
| GB2538324A (en) | 2015-05-15 | 2016-11-16 | Glaxosmithkline Ip Dev Ltd | Packaging cell line for retroviral production |
| GB2538321A (en) | 2015-05-15 | 2016-11-16 | Glaxosmithkline Ip Dev Ltd | Artificial chromosome for retroviral production |
| KR102058113B1 (ko) * | 2015-11-23 | 2019-12-23 | 주식회사 엘지화학 | 접착력이 개선된 리튬 이차전지용 전극 및 이의 제조방법 |
| ES2939617T3 (es) | 2015-11-24 | 2023-04-25 | Glaxosmithkline Ip Dev Ltd | Líneas celulares estables para producción retroviral |
-
2016
- 2016-11-21 FR FR1661254A patent/FR3044017B1/fr not_active Expired - Fee Related
- 2016-11-21 US US15/356,813 patent/US10450574B2/en active Active
- 2016-11-21 JP JP2018526787A patent/JP7110096B2/ja active Active
- 2016-11-21 BR BR112018010639A patent/BR112018010639A2/pt not_active Application Discontinuation
- 2016-11-21 RU RU2018118964A patent/RU2749717C2/ru active
- 2016-11-21 WO PCT/EP2016/078334 patent/WO2017089307A1/en not_active Ceased
- 2016-11-21 KR KR1020187014239A patent/KR102067352B1/ko not_active Expired - Fee Related
- 2016-11-21 CN CN201680068697.3A patent/CN108291211A/zh active Pending
- 2016-11-21 DE DE102016122317.4A patent/DE102016122317A1/de not_active Withdrawn
- 2016-11-21 AU AU2016359838A patent/AU2016359838B2/en not_active Ceased
- 2016-11-21 CA CA3006285A patent/CA3006285A1/en active Pending
- 2016-11-21 EP EP16798223.0A patent/EP3380605A1/en not_active Withdrawn
- 2016-11-21 IT IT102016000117287A patent/IT201600117287A1/it unknown
-
2018
- 2018-05-08 IL IL259223A patent/IL259223B/en unknown
- 2018-05-15 SA SA518391585A patent/SA518391585B1/ar unknown
-
2019
- 2019-10-21 US US16/658,293 patent/US20200063144A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060057553A1 (en) | 2000-05-30 | 2006-03-16 | Estuardo Aguilar-Cordova | Chimeric viral vectors for gene therapy |
| JP2005512573A (ja) | 2001-10-30 | 2005-05-12 | バイレクシス コーポレイション | 調節された核酸発現系 |
| JP2010517554A (ja) | 2007-02-12 | 2010-05-27 | アーク・セラピューティックス・リミテッド | レンチウイルスベクターの作製 |
| JP2015165810A (ja) | 2007-03-23 | 2015-09-24 | ウィスコンシン アラムニ リサーチ ファンデーション | 体細胞の再プログラム化 |
| JP2015529466A (ja) | 2012-09-14 | 2015-10-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター |
Non-Patent Citations (2)
| Title |
|---|
| Teru Kanda，Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system，J Virol.，2004年，78(13)，p.7004-7015 |
| 川口 寧，3. BACシステム : 大腸菌遺伝学とウイルス学が融合した新しいヘルペスウイルスの遺伝子改変法，ウイルス，2004年，54巻2号，P.255-264 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018010639A2 (pt) | 2019-01-22 |
| RU2749717C2 (ru) | 2021-06-16 |
| CA3006285A1 (en) | 2017-06-01 |
| FR3044017B1 (fr) | 2019-05-03 |
| CN108291211A (zh) | 2018-07-17 |
| AU2016359838B2 (en) | 2020-08-06 |
| IL259223A (en) | 2018-07-31 |
| RU2018118964A3 (enExample) | 2020-04-02 |
| FR3044017A1 (fr) | 2017-05-26 |
| US20200063144A1 (en) | 2020-02-27 |
| DE102016122317A1 (de) | 2017-05-24 |
| US20170145427A1 (en) | 2017-05-25 |
| KR20180073624A (ko) | 2018-07-02 |
| US10450574B2 (en) | 2019-10-22 |
| WO2017089307A1 (en) | 2017-06-01 |
| SA518391585B1 (ar) | 2020-10-26 |
| EP3380605A1 (en) | 2018-10-03 |
| IL259223B (en) | 2022-05-01 |
| KR102067352B1 (ko) | 2020-01-16 |
| IT201600117287A1 (it) | 2018-05-21 |
| RU2018118964A (ru) | 2019-12-26 |
| AU2016359838A1 (en) | 2018-05-24 |
| JP2019500030A (ja) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7110096B2 (ja) | レトロウイルス産生のための一時的トランスフェクション法 | |
| AU2016360763B2 (en) | Stable cell lines for retroviral production | |
| JP6878620B2 (ja) | レトロウイルス産生のための安定な細胞株 | |
| GB2538321A (en) | Artificial chromosome for retroviral production | |
| GB2538324A (en) | Packaging cell line for retroviral production | |
| US20250122528A1 (en) | Lentiviral vector | |
| GB2544891A (en) | Transient transfection method for retroviral production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191120 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201028 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210608 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220325 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220624 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220720 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7110096 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |